Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 6:12 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 51 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Human Chorionic Gonadotropin Clear all

Conditions: HCG
Interventions: Human Chorionic Gonadotropin, Placebo, Low calorie diet; Drug · Other
Lead sponsor: Dr. Emma's Corporation; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Colts Neck, New Jersey

Conditions: Infertility
Interventions: HCG is introduced; Drug
Lead sponsor: Servy Massey Fertility Insititute; Other
Eligibility: 21 Years to 47 Years · Female only
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Healthy
Interventions: GE-145 (AN113111) Injection, Visipaque (iodixanol) Injection; Drug
Lead sponsor: GE Healthcare; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Princeton, New Jersey

Conditions: Infertility, Female
Interventions: Low dose hCG; Other
Lead sponsor: Reproductive Medicine Associates of New Jersey; Other
Eligibility: 18 Years to 46 Years · Female only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Basking Ridge, New Jersey

Conditions: Thyroid Gland Follicular Carcinoma, Thyroid Gland Oncocytic Carcinoma, Thyroid Gland Papillary Carcinoma
Interventions: Biospecimen Collection, Cobimetinib, Computed Tomography, Diagnostic Imaging, I-131 Uptake Test, Iodine I-131, Magnetic Resonance Imaging, Positron Emission Tomography, Recombinant Thyrotropin Alfa, Ultrasound Imaging, Vemurafenib; Procedure · Drug · Radiation + 1 more
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Duarte, California

Conditions: Egg Donation
Interventions: Follistim, Ganirelix, Menotropins, Leuprolide, Transvaginal ultrasound guided needle aspiration of oocytes; Drug · Procedure
Lead sponsor: Michigan Reproductive Medicine; Other
Eligibility: 18 Years to 28 Years · Female only
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Bloomfield Hills, Michigan

Conditions: Endometrial Receptivity, Ovarian Hyperstimulation Syndrome
Interventions: GnRH agonist, hCG; Drug
Lead sponsor: UConn Health; Other
Eligibility: 21 Years to 33 Years · Female only
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Farmington, Connecticut

Conditions: Infertility
Interventions: Menotropin, Progestrone vaginal insert, follitropin beta, Progesterone in oil, Ganirelix; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years to 42 Years · Female only
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 7
States / cities: Pasadena, California • San Diego, California • Littleton, Colorado + 4 more

Conditions: Infertility, Diminished Ovarian Reserve, IVF
Interventions: Timing of injectable gonadotropins; Procedure
Lead sponsor: Northwell Health; Other
Eligibility: 20 Years to 45 Years · Female only
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Manhasset, New York

Conditions: Asherman Syndrome, Atrophic Endometrium, Recurrent Implantation Failure
Interventions: Plerixafor; Drug
Lead sponsor: Hugh Taylor; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Orange, Connecticut

Conditions: Polycystic Ovary Syndrome
Interventions: 3-D Ultrasound, recombinant human chorionic gonadotropin, Recombinant human follicle stimulating hormone, Adrenocorticotropin, Dexamethasone, Glucose; Radiation · Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 37 Years · Female only
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: San Diego, California

Conditions: Stroke
Interventions: human chorionic gonadotropin (hCG), then epoetin alfa (EPO), Saline Placebo; Drug
Lead sponsor: Stem Cell Therapeutics Corp.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Orange, California

Conditions: Gonadotropin Deficiency
Interventions: Testosterone 1% Gel, Acyline, Dutasteride, Ketoconazole, HCG, placebo dutasteride, placebo ketoconazole; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 55 Years · Male only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Acute-graft-versus-host Disease
Interventions: Ruxolitinib 10 MG Oral Tablet, hCG, Corticosteroids; Drug
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 12 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Oligospermia, Azoospermia, Nonobstructive, Infertility
Interventions: isotretinoin, Human chorionic gonadotrophin (hCG); Drug
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years to 50 Years · Male only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Polycystic Ovary Syndrome
Interventions: recombinant human chorionic gonadotropin; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Infertility, Subfertility
Interventions: human chorionic gonadotropin (hCG), Placebo Comparator (for hCG); Drug
Lead sponsor: Michigan State University; Other
Eligibility: 18 Years to 34 Years · Female only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Grand Rapids, Michigan

Conditions: Control Media Only, Study hCG and Media
Interventions: hCG at the Time of Embryo Transfer, Control; Other
Lead sponsor: Reproductive Medicine Associates of New Jersey; Other
Eligibility: 18 Years to 43 Years · Female only
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 2
States / cities: Basking Ridge, New Jersey • Allentown, Pennsylvania

Conditions: Infertility
Interventions: AS900672-Enriched 50 microgram (mcg), AS900672-Enriched 100 mcg, AS900672-Enriched 150 mcg, Follitropin alfa 150 international unit (IU), Recombinant human chorionic gonadotropin (r-hCG); Drug
Lead sponsor: Merck KGaA, Darmstadt, Germany; Industry
Eligibility: 18 Years to 36 Years · Female only
Enrollment: 520 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Rockland, Massachusetts

Conditions: Polycystic Ovarian Syndrome, Infertility
Interventions: Menotropin, Progesterone vaginal insert, Follitropin beta, Progesterone in oil, leuprolide acetate; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years to 42 Years · Female only
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 6
States / cities: Littleton, Colorado • Clearwater, Florida • Chicago, Illinois + 3 more

Conditions: Hypogonadism, Spinal Cord Injury
Interventions: Human chorionic gonadotropin (hCG), Luteinizing hormone releasing hormone (LHRH); Drug
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2007
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Pregnancy Related
Interventions: Pregnancy test; Diagnostic Test
Lead sponsor: Voyant Diagnostics, Inc.; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 123 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Infertility, Infertility, Female, Oocyte Retrieval, Postoperative Pain, Embryo Transfer
Interventions: Ketorolac (Toradol), Placebo (saline); Drug · Other
Lead sponsor: Shady Grove Fertility Reproductive Science Center; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 2
States / cities: Rockville, Maryland • Fairfax, Virginia

Conditions: Infertility, Female
Interventions: FET Protocol; Other
Lead sponsor: Reproductive Medicine Associates of New Jersey; Other
Eligibility: 18 Years to 53 Years · Female only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: Basking Ridge, New Jersey • Marlton, New Jersey

Search by objective public record fields.

Muscle-Sparing Effect Of Human Chorionic Gonadotropin (hCG) During a Very Low Calorie Diet (VLCD)

Injection of Hormone to Enhance Implantation in Embryo Transfer After IVF

Single Dose Safety, Tolerance and Pharmacokinetic Study in Healthy Volunteers Undergoing Contrast-enhanced Abdominal Computed Tomography (CT)

Prospective Assessment of Impact of Personalized Dosing of Low-dose Human Chorionic Gonadotropin (hCG) on in Vitro Fertilization (IVF) Outcomes

Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation

Efficacy of Recombinant FSH/GnRH Antagonist Protocol With and Without LH Adjunct for Egg Bank Donation

Gene Expression Profile After Gonadotropin Releasing Hormone (GnRH) Agonist Trigger of Oocyte Maturation

MENOPUR® Versus FOLLISTIM®

The LUTEAL Trial: Luteal Stimulation vs. Estrogen Priming Protocol

Bone Marrow Derived Stem Cells Mobilization for Treatment of Abnormal Endometrium

Mechanisms of Increased Androgen Production Among Women With Polycystic Ovary Syndrome

Study of NTx®-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients

ITT-5 Mechanisms of Spermatogenesis in Man

Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids

Isotretinoin vs hCG for Male Infertility Due to Low or Absent Sperm

Theca Cell Function in Women With Polycystic Ovary Syndrome (PCOS)

Effect of hCG on Receptivity of the Human Endometrium

Intrauterine Human Chorionic Gonadotropin at the Time of Embryo Transfer

Investigation of a Long-Acting Follicle Stimulating Hormone in Infertile Women Undergoing Assisted Reproductive Technology (ART)

Menopur® Versus Follistim® in Polycystic Ovarian Syndrome (PCOS)

Provocative Testing Using LHRH and hCG of the Pituitary-Gonadal Axis in Persons With Spinal Cord Injury.

Feasibility Study of an Automated Point-of-Care Urine Diagnostic Device for Pregnancy

Assessing Ketorolac (Toradol) at Oocyte Retrieval

PRogrammed Versus Modified Natural Cycle After Euploid Failed Embryo Transfer